Glycogen synthase kinase 3: more than a namesake

被引:384
作者
Rayasam, Geetha Vani [1 ]
Tulasi, Vamshi Krishna [1 ]
Sodhi, Reena [1 ]
Davis, Joseph Alex [1 ]
Ray, Abhijit [1 ]
机构
[1] Ranbaxy Res Labs, R&D 3, Dept Pharmacol, Gurgaon, Haryana, India
关键词
diabetes; pancreatic beta cells; beta catenin; Wnt signalling; inhibitors; STIMULATED GLUCOSE-METABOLISM; INSULIN-RECEPTOR SUBSTRATE-1; HUMAN SKELETAL-MUSCLE; CYCLIN-DEPENDENT KINASES; PANCREATIC BETA-CELLS; DIABETIC FATTY RATS; PROTEIN-KINASE; SELECTIVE INHIBITORS; ALZHEIMERS-DISEASE; POTENT INHIBITORS;
D O I
10.1111/j.1476-5381.2008.00085.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glycogen synthase kinase 3 (GSK3), a constitutively acting multi-functional serine threonine kinase is involved in diverse physiological pathways ranging from metabolism, cell cycle, gene expression, development and oncogenesis to neuroprotection. These diverse multiple functions attributed to GSK3 can be explained by variety of substrates like glycogen synthase, tau protein and beta catenin that are phosphorylated leading to their inactivation. GSK3 has been implicated in various diseases such as diabetes, inflammation, cancer, Alzheimer's and bipolar disorder. GSK3 negatively regulates insulin-mediated glycogen synthesis and glucose homeostasis, and increased expression and activity of GSK3 has been reported in type II diabetics and obese animal models. Consequently, inhibitors of GSK3 have been demonstrated to have anti-diabetic effects in vitro and in animal models. However, inhibition of GSK3 poses a challenge as achieving selectivity of an over achieving kinase involved in various pathways with multiple substrates may lead to side effects and toxicity. The primary concern is developing inhibitors of GSK3 that are anti-diabetic but do not lead to up-regulation of oncogenes. The focus of this review is the recent advances and the challenges surrounding GSK3 as an anti-diabetic therapeutic target. British Journal of Pharmacology (2009) doi:10.1111/j.1476-5381.2008.00085.x.
引用
收藏
页码:885 / 898
页数:14
相关论文
共 142 条
[21]   Crystal structure of glycogen synthase kinase 3β:: Structural basis for phosphate-primed substrate specificity and autoinhibition [J].
Dajani, R ;
Fraser, E ;
Roe, SM ;
Young, N ;
Good, V ;
Dale, TC ;
Pearl, LH .
CELL, 2001, 105 (06) :721-732
[22]   Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance [J].
Delibegovic, M ;
Armstrong, CG ;
Dobbie, L ;
Watt, PW ;
Smith, AJH ;
Cohen, PTW .
DIABETES, 2003, 52 (03) :596-604
[23]   Differential regulation of glycogen synthase kinase 3β by insulin and Wnt signaling [J].
Ding, VW ;
Chen, RH ;
McCormick, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (42) :32475-32481
[24]   Functional redundancy of GSK-3α and GSK-3β in Wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines [J].
Doble, Bradley W. ;
Patel, Satish ;
Wood, Geoffrey A. ;
Kockeritz, Lisa K. ;
Woodgett, James R. .
DEVELOPMENTAL CELL, 2007, 12 (06) :957-971
[25]   GSK-3: tricks of the trade for a multi-tasking kinase [J].
Doble, BW ;
Woodgett, JR .
JOURNAL OF CELL SCIENCE, 2003, 116 (07) :1175-1186
[26]   Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle [J].
Dokken, BB ;
Sloniger, JA ;
Henriksen, EJ .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2005, 288 (06) :E1188-E1194
[27]   Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats [J].
Dokken, Betsy B. ;
Henriksen, Erik J. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 291 (02) :E207-E213
[28]   Mechanisms of β-cell death in type 2 diabetes [J].
Donath, MY ;
Ehses, JA ;
Maedler, K ;
Schumann, DM ;
Ellingsgaard, H ;
Eppler, E ;
Reinecke, M .
DIABETES, 2005, 54 :S108-S113
[29]   Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice [J].
Eldar-Finkelman, H ;
Schreyer, SA ;
Shinohara, MM ;
LeBoeuf, RC ;
Krebs, EG .
DIABETES, 1999, 48 (08) :1662-1666
[30]   Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment [J].
Eldar-Finkelman, H ;
Ilouz, R .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (09) :1511-1519